BD Announces Results for Fourth Fiscal Quarter and Full Year

FRANKLIN LAKES, N.J., Nov. 4 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson
and Company) (NYSE: BDX) today reported quarterly revenues of $1.898 billion
for the fourth fiscal quarter ended September 30, 2009, representing an
increase of 5 percent from the prior-year period, or 8 percent excluding the
unfavorable impact from foreign currency translation.

For the full fiscal year ended September 30, 2009, BD reported revenues of
$7.161 billion, representing an increase of 1 percent over the prior year, or
5 percent excluding the unfavorable impact from foreign currency translation.

"The achievement of solid fourth quarter performance, in particular BD Medical
and BD Diagnostics, marks the conclusion of another successful year for BD,"
said Edward J. Ludwig, Chairman and Chief Executive Officer. "This strong
finish to the year provides a platform for growth in fiscal 2010 and gives us
confidence we will achieve our stated long-term goals."

Fourth Quarter Earnings and Analysis of Full Fiscal Year 2009 and 2008
Earnings
Reported diluted earnings per share from continuing operations of $1.25 for
the fourth quarter of 2009 increased by 13 percent over reported diluted
earnings per share from continuing operations of $1.11 for the fourth quarter
of 2008. On a currency-neutral basis, diluted earnings per share from
continuing operations for the fourth quarter of fiscal 2009 increased 17
percent.

(Table 1) Twelve Months Ended September 30,
--------- -----------------------------------
FY2009 FY2008 % Change FXN % Change
------ ------ -------- ------------

Diluted EPS from Continuing
Operations: $4.92 $4.42 11%

Specified Items:
----------------
Litigation Charge (1) $0.11
Tax Adjustment (2) (0.08)
----- -----
Adjusted Diluted EPS from
Continuing Operations: $4.95 $4.42 12% 10%
===== ===== === ===

(1) Represents the charge relating to the pending settlement with the direct
purchaser plaintiffs (which includes BD's distributors) in the antitrust class
actions.
(2) Represents the tax benefit relating to various tax settlements in multiple
jurisdictions.

The preceding analysis (Table 1) of diluted earnings per share from continuing
operations for the twelve-month periods ended September 30, 2009 and 2008
identifies the specified items that affect comparability of results between
periods. As illustrated, fiscal year 2009 diluted earnings per share from
continuing operations of $4.92 included the third quarter tax benefit of 8
cents and the second quarter charge of 11 cents relating to a pending
antitrust class action settlement. Excluding these specified items, diluted
earnings per share from continuing operations for the twelve-month period in
fiscal year 2009 were $4.95, representing an increase of 12 percent over
diluted earnings per share from continuing operations of $4.42 from the
prior-year period. On a currency-neutral basis, adjusted diluted earnings per
share from continuing operations for the twelve-month period ending September
30, 2009 increased 10 percent.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1 billion,
representing an increase of 8 percent from the prior-year period, or 13
percent excluding the unfavorable impact from foreign currency translation.
Strong sales of Pharmaceutical Systems products, as expected, and solid sales
of Medical Surgical Systems products contributed to revenue growth; both
included a favorable impact from flu-related sales. For the twelve-month
period ended September 30, 2009, the BD Medical segment reported flat revenue
growth. On a currency-neutral basis, BD Medical revenues for the twelve-month
period increased by 6 percent to $3.731 billion.

In the BD Diagnostics segment, worldwide revenues for the quarter were $580
million, representing an increase of 5 percent from the prior-year period or 8
percent excluding the unfavorable impact from foreign currency translation.
Sales of safety-engineered devices, cancer diagnostics products and infectious
disease testing systems, including flu-related products, contributed to
revenue growth. For the twelve-month period ended September 30, 2009, the BD
Diagnostics segment reported 3 percent revenue growth to $2.226 billion. On a
currency-neutral basis, BD Diagnostics revenues for the twelve-month period
increased by 7 percent.

In the BD Biosciences segment, worldwide revenues for the quarter were $312
million, representing a decrease of 5 percent from the prior-year period, or a
decrease of 4 percent excluding the unfavorable impact from foreign currency
translation. Demand in the U.S. for capital equipment in the research and
clinical segments continued to be impacted by funding constraints.
International revenue growth continued to moderate as well. For the
twelve-month period ended September 30, 2009, the BD Biosciences segment
reported 1 percent revenue growth to $1.204 billion. On a currency-neutral
basis, BD Biosciences revenues for the twelve-month period increased by 2
percent.

Geographic Results
Fourth quarter revenues in the U.S. were $840 million, representing an
increase of 6 percent from the prior-year period. Revenues outside of the
U.S. were $1.058 billion, representing an increase of 4 percent from the
prior-year period, or 10 percent excluding the unfavorable impact from foreign
currency translation.

For the twelve-month period ended September 30, 2009, revenues in the U.S.
were $3.205 billion, representing an increase of 3 percent from the prior-year
period. Revenues outside of the U.S. were $3.956 billion, representing flat
growth from the prior-year period, or 7 percent growth excluding the
unfavorable impact from foreign currency translation.

Fiscal 2010 Outlook for Full Year
The Company estimates that reported revenues for the full fiscal year 2010
will increase about 6 percent, or 5 to 6 percent excluding the estimated
favorable impact from foreign currency translation.

The Company expects diluted earnings per share from continuing operations for
the full fiscal year 2010 to increase approximately 1 to 3 percent over
adjusted diluted earnings per share from continuing operations, excluding
specified items, of $4.95 for the fiscal year 2009, or 7 to 9 percent
excluding the estimated unfavorable impact from foreign currency translation.

Conference Call Information
A conference call regarding BD's fourth fiscal quarter and full year results
and its expectations for fiscal year 2010 will be broadcast live on BD's
website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET)
Wednesday, November 4, 2009. The conference call will be available for replay
through the close of business on November 11, 2009 on BD's website,
www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291
(international), access code 34687454.

This news release contains certain non-GAAP financial measures. A
reconciliation of these and other measures to the comparable GAAP measures is
included in this release and in the attached financial tables, as well as in
the Form 8-K that BD filed today with the SEC.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000
associates in approximately 50 countries throughout the world. The Company
serves healthcare institutions, life science researchers, clinical
laboratories, the pharmaceutical industry and the general public. For more
information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2010 Outlook for
Full Year," contains certain estimates and other forward-looking statements
(as defined under Federal securities laws) regarding BD's performance,
including future revenues, earnings per share and income, or events or
developments that BD expects to occur or anticipates occurring in the future.
All such statements are based upon current expectations of BD and involve a
number of business risks and uncertainties. Actual results could vary
materially from anticipated results described, implied or projected in any
forward-looking statement. With respect to forward-looking statements
contained herein, a number of factors could cause actual results to vary
materially from any forward-looking statement. For instance, various
healthcare reform proposals, if enacted, would impose an excise tax applicable
to medical device manufacturers, including BD, and these may be effective in
calendar year 2010. Other factors include, but are not limited to: adverse
changes in regional, national or foreign economic conditions, including any
impact that may result from the current global economic downturn on our
ability to access credit markets and finance our operations, the demand for
our products and services, or our suppliers' ability to provide products
needed for our operations; changes in interest or foreign currency exchange
rates, particularly in light of increased volatility in currency exchange
rates; potential healthcare reform, including changes in government pricing
and reimbursement policies or other cost containment reforms; competitive
factors; pricing and market share pressures; difficulties inherent in product
development and delays in product introductions; increases in energy costs and
their effect on, among other things, the cost of producing BD's products;
fluctuations in costs and availability of raw materials and in BD's ability to
maintain favorable supplier arrangements and relationships; uncertainties of
litigation (as described in BD's filings with the Securities and Exchange
Commission); the effects of potential pandemic diseases; our ability to
successfully integrate any businesses we acquire; and issuance of new or
revised accounting standards, as well as other factors discussed in BD's
filings with the Securities and Exchange Commission. We do not intend to
update any forward-looking statements to reflect events or circumstances after
the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

Three Months Ended September 30,
2009 2008 % Change
---------- ---------- --------

REVENUES $1,897,733 $1,812,156 4.7

Cost of products sold 911,911 880,372 3.6
Selling and administrative 432,477 432,399 0.0
Research and development 113,737 108,463 4.9
------------------------ ------- ------- ----
TOTAL OPERATING COSTS
AND EXPENSES 1,458,125 1,421,234 2.6
----------------- --------- --------- ----

OPERATING INCOME 439,608 390,922 12.5

Interest income 14,418 6,879 NM
Interest expense (13,782) (8,889) 55.0
Other expense, net (3,312) (1,734) NM
------------------ ------ ------ ----

INCOME FROM CONTINUING
OPERATIONS BEFORE
INCOME TAXES 436,932 387,178 12.9

Income tax provision 131,175 108,216 21.2
-------------------- ------- ------- ----

INCOME FROM CONTINUING
OPERATIONS 305,757 278,962 9.6

INCOME FROM DISCONTINUED
OPERATIONS NET OF INCOME
TAX PROVISION OF $3,334
AND $1,222,
RESPECTIVELY 11,463 3,212 NM
------------------ ------ ----- ----

NET INCOME $317,220 $282,174 12.4
---------- -------- -------- ----

EARNINGS PER SHARE

Basic:
Income from continuing
operations $1.28 $1.14 12.3
Income from discontinued
operations $0.05 $0.01 NM
Net income (1) $1.33 $1.16 14.7

Diluted:
Income from continuing
operations $1.25 $1.11 12.6
Income from discontinued
operations $0.05 $0.01 NM
Net income (1) $1.29 $1.12 15.2

AVERAGE SHARES OUTSTANDING

Basic 239,162 243,863
Diluted 245,056 251,197
------------ ------- -------

NM - Not Meaningful
(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

Twelve Months Ended September 30,
2009 2008 % Change
---------- ---------- --------

REVENUES $7,160,874 $7,074,942 1.2

Cost of products sold 3,397,598 3,446,838 (1.4)
Selling and administrative 1,704,795 1,695,610 0.5
Research and development 408,128 395,631 3.2
------------------------ ------- ------- ----
TOTAL OPERATING COSTS
AND EXPENSES 5,510,521 5,538,079 (0.5)
----------------- --------- --------- ----

OPERATING INCOME 1,650,353 1,536,863 7.4

Interest income 33,148 39,368 (15.8)
Interest expense (40,389) (36,343) 11.1
Other expense, net (3,850) (1,484) NM
------------------ ------ ------ ----

INCOME FROM CONTINUING
OPERATIONS BEFORE
INCOME TAXES 1,639,262 1,538,404 6.6

Income tax provision 426,208 422,537 0.9
-------------------- ------- ------- ----

INCOME FROM CONTINUING
OPERATIONS 1,213,054 1,115,867 8.7

INCOME FROM DISCONTINUED
OPERATIONS NET OF INCOME
TAX PROVISION OF
$5,014 AND $2,585,
RESPECTIVELY 18,549 11,129 NM
------------------------- ------ ------ ----

NET INCOME $1,231,603 $1,126,996 9.3
---------- ---------- ---------- ----

EARNINGS PER SHARE

Basic:
Income from continuing
operations $5.04 $4.57 10.3
Income from discontinued
operations $0.08 $0.05 NM
Net income (1) $5.12 $4.61 11.1

Diluted:
Income from continuing
operations $4.92 $4.42 11.3
Income from discontinued
operations $0.08 $0.04 NM
Net income (1) $4.99 $4.46 11.9

AVERAGE SHARES OUTSTANDING

Basic 240,479 244,323
Diluted 246,798 252,681
------- ------- -------

NM - Not Meaningful
(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

Three Months Ended September 30,
2009 2008 % Change
-------- ---------- --------

BD MEDICAL
----------
United States $410,925 $374,487 9.7
International 594,573 555,109 7.1
---------------- ------- ------- ---
TOTAL $1,005,498 $929,596 8.2
----- ---------- -------- ---

BD DIAGNOSTICS
--------------
United States $305,488 $281,148 8.7
International 274,521 271,918 1.0
---------------- ------- ------- ---
TOTAL $580,009 $553,066 4.9
----- -------- -------- ---

BD BIOSCIENCES
--------------
United States $123,225 $136,749 (9.9)
International 189,001 192,745 (1.9)
---------------- ------- ------- ----
TOTAL $312,226 $329,494 (5.2)
----- -------- -------- ----

TOTAL REVENUES
--------------
United States $839,638 $792,384 6.0
International 1,058,095 1,019,772 3.8
---------------- --------- --------- ---
TOTAL $1,897,733 $1,812,156 4.7
----- ---------- ---------- ---

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

Twelve Months Ended September 30,
2009 2008 % Change
---------- ---------- --------

BD MEDICAL
----------
United States $1,577,986 $1,524,204 3.5
International 2,152,860 2,195,831 (2.0)
---------------- --------- --------- ----
TOTAL $3,730,846 $3,720,035 0.3
----- ---------- ---------- ---

BD DIAGNOSTICS
--------------
United States $1,177,543 $1,121,843 5.0
International 1,048,676 1,037,968 1.0
---------------- --------- --------- ---
TOTAL $2,226,219 $2,159,811 3.1
----- ---------- ---------- ---

BD BIOSCIENCES
--------------
United States $449,151 $470,641 (4.6)
International 754,658 724,455 4.2
---------------- ------- ------- ---
TOTAL $1,203,809 $1,195,096 0.7
----- ---------- ---------- ---

TOTAL REVENUES
--------------
United States $3,204,680 $3,116,688 2.8
International 3,956,194 3,958,254 (0.1)
---------------- --------- --------- ----
TOTAL $7,160,874 $7,074,942 1.2
----- ---------- ---------- ---

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

United States
----------------------------
2009 2008 % Change
-------- -------- ----------

BD MEDICAL
----------
Medical Surgical Systems $267,070 $248,111 7.6
Diabetes Care 88,590 82,445 7.5
Pharmaceutical Systems 48,353 37,512 28.9
Ophthalmic Systems 6,912 6,419 7.7
--------------------- ----- ----- ---
TOTAL $410,925 $374,487 9.7
----- -------- -------- ---

BD DIAGNOSTICS
--------------
Preanalytical Systems $156,328 $145,987 7.1
Diagnostic Systems 149,160 135,161 10.4
--------------------- ------- ------- ----
TOTAL $305,488 $281,148 8.7
----- -------- -------- ---

BD BIOSCIENCES
--------------
Cell Analysis $84,179 $98,883 (14.9)
Discovery Labware 39,046 37,866 3.1
-------------------- ------ ------ ---
TOTAL $123,225 $136,749 (9.9)
----- -------- -------- ----

TOTAL UNITED STATES $839,638 $792,384 6.0
------------------- -------- -------- ---

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

International
-----------------------------------------------------
% Change
---------------------------------
2009 2008 Reported FX Neutral FX Impact
-------- -------- ---------- ---------- ---------

BD MEDICAL
----------
Medical
Surgical
Systems $265,904 $261,190 1.8 11.0 (9.2)
Diabetes Care 92,098 92,593 (0.5) 5.1 (5.6)
Pharmaceutical
Systems 224,195 188,773 18.8 26.7 (7.9)
Ophthalmic
Systems 12,376 12,553 (1.4) 5.4 (6.8)
------------- ------ ------ ---- --- ----
TOTAL $594,573 $555,109 7.1 15.2 (8.1)
----- -------- -------- --- ---- ----

BD DIAGNOSTICS
--------------
Preanalytical
Systems $138,297 $141,119 (2.0) 5.5 (7.5)
Diagnostic
Systems 136,224 130,799 4.1 8.7 (4.6)
------------- ------- ------- --- --- ----
TOTAL $274,521 $271,918 1.0 7.0 (6.0)
----- -------- -------- --- --- ----

BD BIOSCIENCES
--------------
Cell Analysis $150,055 $154,719 (3.0) (0.3) (2.7)
Discovery
Labware 38,946 38,026 2.4 3.4 (1.0)
------------ ------ ------ --- --- ----
TOTAL $189,001 $192,745 (1.9) 0.4 (2.3)
----- -------- -------- ---- --- ----

TOTAL
INTERNATIONAL $1,058,095 $1,019,772 3.8 10.2 (6.4)
-------------- ---------- ---------- --- ---- ----

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

Total
-----------------------------------------------------
% Change
---------------------------------
2009 2008 Reported FX Neutral FX Impact
-------- -------- ---------- ---------- ---------

BD MEDICAL
-----------
Medical
Surgical
Systems $532,974 $509,301 4.6 9.3 (4.7)
Diabetes Care 180,688 175,038 3.2 6.2 (3.0)
Pharmaceutical
Systems 272,548 226,285 20.4 27.1 (6.7)
Ophthalmic
Systems 19,288 18,972 1.7 6.2 (4.5)
------------- ------ ------ --- --- ----
TOTAL $1,005,498 $929,596 8.2 13.0 (4.8)
----- ---------- -------- --- ---- ----

BD DIAGNOSTICS
--------------
Preanalytical
Systems $294,625 $287,106 2.6 6.3 (3.7)
Diagnostic
Systems 285,384 265,960 7.3 9.5 (2.2)
------------- ------- ------- --- --- ----
TOTAL $580,009 $553,066 4.9 7.8 (2.9)
----- -------- -------- --- --- ----

BD BIOSCIENCES
--------------
Cell Analysis $234,234 $253,602 (7.6) (6.0) (1.6)
Discovery
Labware 77,992 75,892 2.8 3.3 (0.5)
------------ ------ ------ --- --- ----
TOTAL $312,226 $329,494 (5.2) (3.8) (1.4)
----- -------- -------- ---- ---- ----

TOTAL REVENUES $1,897,733 $1,812,156 4.7 8.4 (3.7)
-------------- ---------- ---------- --- --- ----

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

United States
--------------------------------
2009 2008 % Change
---------- --------- ---------

BD MEDICAL
----------
Medical Surgical Systems $1,021,846 $977,262 4.6
Diabetes Care 351,618 332,545 5.7
Pharmaceutical Systems 177,529 189,394 (6.3)
Ophthalmic Systems 26,993 25,003 8.0
--------------------- ------ ------ ---
TOTAL $1,577,986 $1,524,204 3.5
----- ---------- ---------- ---

BD DIAGNOSTICS
--------------
Preanalytical Systems $608,754 $574,378 6.0
Diagnostic Systems 568,789 547,465 3.9
--------------------- ------- ------- ---
TOTAL $1,177,543 $1,121,843 5.0
----- ---------- ---------- ---

BD BIOSCIENCES
--------------
Cell Analysis $303,846 $324,698 (6.4)
Discovery Labware 145,305 145,943 (0.4)
-------------------- ------- ------- ----
TOTAL $449,151 $470,641 (4.6)
----- -------- -------- ----

TOTAL UNITED STATES $3,204,680 $3,116,688 2.8
------------------- ---------- ---------- ---

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

International
------------------------------------------------
% Change
--------------------------------
2009 2008 Reported FX Neutral FX Impact
---- ---- ---------- ---------- ---------

BD MEDICAL
----------
Medical Surgical
Systems $963,083 $1,027,592 (6.3) 4.5 (10.8)
Diabetes Care 363,319 361,807 0.4 7.9 (7.5)
Pharmaceutical
Systems 774,914 752,742 2.9 10.9 (8.0)
Ophthalmic
Systems 51,544 53,690 (4.0) 4.1 (8.1)
------------- ------ ------ ---- --- ----
TOTAL $2,152,860 $2,195,831 (2.0) 7.2 (9.2)
----- ---------- ---------- ---- --- ----

BD DIAGNOSTICS
--------------
Preanalytical
Systems $534,677 $549,150 (2.6) 6.8 (9.4)
Diagnostic
Systems 513,999 488,818 5.2 11.2 (6.0)
------------- ------- ------- --- ---- ----
TOTAL $1,048,676 $1,037,968 1.0 8.9 (7.9)
----- ---------- ---------- --- --- ----

BD BIOSCIENCES
--------------
Cell Analysis $600,671 $575,813 4.3 5.9 (1.6)
Discovery
Labware 153,987 148,642 3.6 4.2 (0.6)
------------ ------- ------- --- --- ----
TOTAL $754,658 $724,455 4.2 5.5 (1.3)
----- -------- -------- --- --- ----

TOTAL
INTERNATIONAL $3,956,194 $3,958,254 (0.1) 7.4 (7.5)
-------------- ---------- ---------- ---- --- ----

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

Total
-------------------------------------------------
% Change
--------------------------
FX FX
2009 2008 Reported Neutral Impact
---------- ---------- -------- ------ ------
BD MEDICAL
-----------
Medical Surgical
Systems $1,984,929 $2,004,854 (1.0) 4.5 (5.5)
Diabetes Care 714,937 694,352 3.0 6.8 (3.8)
Pharmaceutical
Systems 952,443 942,136 1.1 7.4 (6.3)
Ophthalmic
Systems 78,537 78,693 (0.2) 5.3 (5.5)
------------- ------ ------ ---- --- -----
TOTAL $3,730,846 $3,720,035 0.3 5.7 (5.4)
----- ---------- ---------- --- --- -----

BD DIAGNOSTICS
--------------
Preanalytical
Systems $1,143,431 $1,123,528 1.8 6.4 (4.6)
Diagnostic
Systems 1,082,788 1,036,283 4.5 7.4 (2.9)
------------- --------- --------- --- --- -----
TOTAL $2,226,219 $2,159,811 3.1 6.8 (3.7)
----- ---------- ---------- --- --- -----

BD BIOSCIENCES
--------------
Cell Analysis $904,517 $900,511 0.4 1.4 (1.0)
Discovery
Labware 299,292 294,585 1.6 1.9 (0.3)
------------ ------- ------- --- --- -----
TOTAL $1,203,809 $1,195,096 0.7 1.5 (0.8)
----- ---------- ---------- --- --- -----

TOTAL REVENUES $7,160,874 $7,074,942 1.2 5.4 (4.2)
-------------- ---------- ---------- --- --- -----

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

Three Months Ended September 30,
-------------------------------------------------
% Change
-------------------------------
2009 2008 Reported FX Neutral FX Impact
-------- -------- ---------- ---------- ---------

TOTAL SAFETY REVENUES
---------------------
United States $282,286 $261,007 8.2 8.2 -
International 150,906 143,258 5.3 13.5 (8.2)
---------------- ------- ------- --- ---- ----
TOTAL $433,192 $404,265 7.2 10.0 (2.8)
----- -------- -------- --- ---- ----

BY SEGMENT:
-----------
BD Medical $211,049 $191,813 10.0 12.1 (2.1)
BD Diagnostics 222,143 212,452 4.6 8.1 (3.5)
----------------- ------- ------- --- --- ----
TOTAL $433,192 $404,265 7.2 10.0 (2.8)
----- -------- -------- --- ---- ----

Twelve Months Ended September 30,
-----------------------------------------------
% Change
-------------------------------
2009 2008 Reported FX Neutral FX Impact
--------- ---------- --------- ---------- ---------

TOTAL SAFETY REVENUES
---------------------
United States $1,079,000 $1,035,615 4.2 4.2 -
International 570,674 534,055 6.9 17.3 (10.4)
---------------- ------- ------- --- ---- -----
TOTAL $1,649,674 $1,569,670 5.1 8.6 (3.5)
----- ---------- ---------- --- --- ----

BY SEGMENT:
-----------
BD Medical $786,033 $748,722 5.0 7.7 (2.7)
BD Diagnostics 863,641 820,948 5.2 9.5 (4.3)
-------------- ------- ------- --- --- ----
TOTAL $1,649,674 $1,569,670 5.1 8.6 (3.5)
----- ---------- ---------- --- --- ----

SOURCE BD (Becton, Dickinson and Company)

Patricia A. Spinella, Investor Relations, +1-201-847-5453, or Colleen T.
White, Corporate Communications, +1-201-847-5369, both of BD